China Biologic Products Holdings EBIT

China Biologic Products Holdings (CBPO) currently reports a EBIT of $190M as of December 2020. That compares with $170M in the prior-year period — up 16.5% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore China Biologic Products Holdings's EBIT history and peer comparisons.

China Biologic Products Holdings's EBIT increased from $170M to $190M — a 16.5% year-over-year increase (period ending December 2020). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

China Biologic Products Holdings's EBIT of $190M is lower than the Healthcare sector average of $23B. That is roughly 99.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

China Biologic Products Holdings reported $190M in EBIT as of December 2020. That compares with $170M in the prior-year period — up 16.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $190M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for China Biologic Products Holdings, and consider following CBPO for alerts when major investors trade the stock.